Phase 2 Pancreatic Cancer Trial, Recruiting NCT07575191 Sponsor: Smartwise Sweden AB Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT07575191
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older.
  • You have been diagnosed with locally advanced pancreatic cancer, confirmed by a tissue sample (biopsy).
  • You have been receiving chemotherapy through an IV for at least six months.
  • You are generally well enough to carry out daily activities with little to no limitation (confirm with trial site regarding specific fitness level required).
  • Your cancer has not spread to other parts of the body, and your condition is either stable or only growing locally, as confirmed by a specialist team within the last 4 weeks.
  • Your pancreatic cancer cannot be removed by surgery, as confirmed by a specialist team within the last 4 weeks.
  • Your tumor can be measured using standard imaging guidelines.
  • Your blood counts, liver function, and kidney function are within acceptable ranges (confirm with trial site for specific values).
  • You are able to attend all scheduled appointments, undergo procedures, complete required forms, and give written consent to participate.
  • If you are a woman who could become pregnant, you must have a negative pregnancy test at the start and agree to use highly effective contraception during the trial and for 6 months after your last treatment.
  • If you are a man who could father a child, you must agree to use highly effective contraception during the trial and for 3 months after your last treatment, and avoid donating sperm during this time.

Who may not be able to join:

  • You are currently taking part in another clinical trial that may affect the results of this one.
  • You are unable to give informed consent to participate.
  • Your pancreatic cancer is not the most common type (adenocarcinoma) — for example, neuroendocrine tumours or cancer that has spread from elsewhere would not be eligible (a type called adenosquamous is allowed).
  • Your cancer has spread to other organs or distant lymph nodes.
  • Your cancer stage is unknown or your cancer has come back after previous treatment.
  • You have a medical reason why you cannot receive the chemotherapy drug Gemcitabine.
  • You cannot receive iodine-based contrast dye used in certain scans.
  • There are physical structures in your body that would prevent the treatment from reaching the tumour (confirm with trial site).
  • You have had another cancer in the past, unless you have been cancer-free for 3 or more years (some exceptions may apply — confirm with trial site).
  • You have other serious unmanaged health conditions, including mental health conditions or difficult personal circumstances, that could make it unsafe or difficult for you to take part.
  • You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +46 70 842 10 54

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Smartwise Sweden AB
Registry
ClinicalTrials.gov
Start date
29 April 2026
Est. completion
1 December 2027

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Extroducer® related Serious Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov